Bio-Rad Laboratories FY 2021: revenue $2.9B, up 15%; diluted EPS $140.56

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$2.9B+15% from $2.5B in FY 202010-K income statement, on EDGAR
2. Net income$4.2B+12% from $3.8B in FY 202010-K income statement, on EDGAR
3. Diluted EPS$140.56+11% from $126.20 in FY 202010-K income statement, on EDGAR
4. Cash and cash equivalents$470.8M−29% from $662.2M in FY 2020Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$656.5M+14% from $575.3M in FY 202010-K cash flow statement, on EDGAR

Every year in the financial tables